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Background: Venous thromboembolic co-morbidities can have a significant impact on treatment response,
treatment options, quality of life, and ultimately, survival from cancer. The extent of venous thromboembolic co-
morbidity among older renal cell cancer patients is poorly described in the literature. It is important to understand
the scope of venous thromboembolic events, before and after diagnosis, in order to offer renal cell cancer patients
optimal care and improved quality of life.
Methods: The main goal of this study was to estimate and describe the incidence of venous thromboembolic
events before and after renal cell cancer diagnosis. SEER-Medicare linked data (1991–2003) was utilized for this
retrospective cohort analysis (n = 11,950) of older renal cell cancer patients (≥ 65 years). Incidence rates and
proportions in addition to multivariable Cox proportional hazard and logistic regression models were utilized to
describe the incidence and relative risk of venous thromboembolic events.
Results: We observed that in the 12 months after diagnosis, 8.3% of renal cell cancer patients experienced a deep
venous thrombosis, 2.4% experienced a pulmonary embolism, and 3.9% experienced other thromboembolic events.
Nearly 70% of venous thromboembolic events occurred in the first 90 days after renal cell cancer diagnosis. Renal
cell cancer patients were 2–4 times more likely to have a venous thromboembolic event in the 12 months after
cancer diagnosis than non-cancer patients followed during the same time frame. Recent history of a venous event
substantially increased the risk of that same event in the 12 months after diagnosis (HR = 5.2-18.8).
Conclusion: Venous thromboembolic events are common and serious co-morbidities that should be closely
monitored in older renal cell cancer patients, particularly during the first 3 months following diagnosis and among
those with a recent history of a venous thromboembolic event.
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Venous thromboembolic co-morbidities among cancer
patients can have a significant impact on treatment re-
sponse, treatment options, quality of life, and ultimately,
survival from cancer [1-3]. Although it has been estimated
that 1 in 200 cancer patients will experience venous
thromboembolic events (VTEs), annually [4]; a detailed
analysis of VTEs by cancer type is not available in the lit-
erature. A small body of evidence is developing for brain,
breast, lung, ovarian, and pancreatic cancers, suggesting
that the incidence of VTEs varies substantially by cancer
subtype [2,5-14]. Estimates for these cancers range from
as low as 0.4% up to 26.0%, depending on the cancer type,
study population, and the length of follow-up [13]. Be-
cause each cancer is a distinct disease, it is important to
carefully characterize this co-morbidity by cancer subtype.
The extent of venous thromboembolic co-morbidity
among older renal cell cancer (RCC) patients is poorly
described in the literature: timing of VTEs has not been
thoroughly investigated, cofactors have not been ad-
equately considered, VTE subgroups have not been eval-
uated, older subgroups have not been studied, and the
broader diagnosis category of kidney cancer has been
used instead of the more specific diagnosis of RCC. It is
important to understand the scope of VTEs, before and
after diagnosis, in order to offer RCC patients optimal
care and improved quality of life.
The primary objectives of this study were 1) to esti-
mate the incidence of VTEs before RCC diagnosis and
during various time periods after RCC diagnosis 2) to
produce adjusted relative risk estimates of VTEs for
RCC patients with and without a cardiovascular disease
or VTE history and 3) to compare risk of VTEs for RCC
patients versus age-matched non-cancer individuals.
Methods
Study population
SEER-Medicare data is a linkage of U.S. cancer registry
data with Medicare claims data. This database combines
two large, population-based, geographically diverse U.S.
data sources, providing detailed information about eld-
erly persons (≥65 years) with and without cancer. Data
from 1991–2003 were utilized for this retrospective co-
hort analysis. Patients 65 years of age and over who were
diagnosed with RCC and had at least 24 months of con-
tinuous non-HMO Medicare coverage (Parts A and B)
before diagnosis and 1 to 12 months after diagnosis were
included in the cancer cohort. Duration of patient follow-
up after diagnosis (maximum 12 months) was the number
of months until the patient died or lost Medicare cover-
age. If neither of these events occurred before the end of
the planned follow-up time after diagnosis, the patient
was followed for the full 12 months. Non-cancer patients
were frequency-matched by age to cancer patients at aratio of 1:1. VTEs of interest were deep vein thrombosis
(DVT), pulmonary embolism (PE), and other thrombo-
embolic events (OTE). ICD-9 diagnosis codes were used
to identify VTEs and ICD-O-3 codes were used to identify
RCC patients. DVT was captured using ICD-9 codes of
451.1 (451.11, 451.19) 451.2, 451.81, 451.83, 451.84, 453.1,
453.2, 453.4 (453.40, 453.41, 453.42) 453.8, and 453.9; PE
was captured using ICD-9 codes of 415.1 and 415.19.
OTEs were captured using ICD-9 codes of 362.35, 362.36,
437.6, 451.0, 451.82, 451.89, 451.9, 453.0, 453.3, and 452.
Renal Cell Carcinoma (RCC) was captured using ICD-O-3
of C649 excluding histologies 8050–8130 (inclusive) and
any leukemias and lymphomas of the renal pelvis.
Statistical analysis
RCC patients
Incidence rates of each VTE a) in the 12 months before
diagnosis and b) in the 12 months after diagnosis were
described by age, race, sex, stage at diagnosis, and year
of diagnosis. The numerator is the number of events
that occurred over the respective 12-month period and
the denominator is the person-years at risk. Events in
the 12 months after diagnosis were further described as
the proportion of cases with a first event in discrete time
intervals of follow-up time (0–90 days, 91–180 days,
181–270 days, and 271–365 days). The numerator of
each incidence proportion is the number of persons with
their first event of interest during that time period only,
while the denominator represents the persons who were
alive and free of events at the beginning of the period.
The Cox proportional hazard model was used to build
predictive models to identify important risk factors for
each VTE of interest among RCC patients. Potential risk
factors included in the initial (full) model were as follows:
age at diagnosis, race, sex, diabetes, hypercholesterolemia,
atherosclerosis, varicose veins, recent high-risk surgical
procedure, central venous catheter, sickle cell anemia, kid-
ney disease, stage at diagnosis, chemotherapy, immuno-
therapy, hormone therapy, surgery of primary site, history
of cancer, and recent history of VTE. Risk factors with a
multivariable p-value <0.1 were retained in the final multi-
variable predictive model.
Relative incidence rates of VTEs in RCC patients with
a recent history of cardiovascular event (CVD) or VTE
event (12 months before diagnosis) versus RCC patients
without such a recent history were calculated using the
Cox proportional hazard models. History of CVD event
was defined as any of the following events in the 12 months
before RCC diagnosis: myocardial infarction, ischemic
stroke, congestive heart failure, angina, or TIA. The first
VTE was counted for each patient from time of diagnosis
up to 12 months after diagnosis. Potential confounders and
effect measure modifiers, identified through ICD-9 diagno-
sis and procedure codes, were as follows: age at diagnosis,
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varicose veins, recent high-risk surgical procedure (cardiac
or vascular surgeries in the year after RCC diagnosis), cen-
tral venous catheter, sickle cell anemia, kidney disease,
stage at diagnosis, chemotherapy, nephrectomy, immuno-
therapy, hormone therapy, history of cancer, recent history
of CVD event, and recent history of VTE.RCC vs. Non-cancer patients
A matched-cohort design was utilized to compare rates
of VTEs among RCC and similar non-cancer patients.
Multivariable logistic regression analysis was used to
evaluate the relative risk of VTEs in RCC patients
(12 months before diagnosis) versus non-cancer cases
(12 months before index date). Relative incidence rate
of VTEs in RCC patients (12 months after diagnosis)
versus non-cancer cases (12 months after index date)
was calculated using multivariable Cox proportional
hazard models. Potential confounders and effect meas-
ure modifiers (refer to previous section) were assessed
and all models were adjusted for age to account for the
age-matched design. Sas 9.1 was used to perform all
analyses.
This data analysis was approved by our protocol re-
view forum for scientific merit. Because we analyzed sec-
ondary, observational data which was anonymized and
distributed by the National Cancer Institute (SEER-
Medicare data), this project was not reviewed separately
by an ethics committee. Representatives from the NCITable 1 Unadjusted incidence rates of VTEs among older RCC
Data (1991–2003)a












Rate ratio (after vs. before)d
aVTE = venous thromboembolic events; RCC = renal cell cancer; DVT = Deep Vein Th
category includes the following diagnoses: central retinal vein occlusion, venous tri
sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebiti
thrombophlebitis of other sites, gout with other specified manifestations, Budd-Chi
bn = number of VTE events; p-y = person-years.
cRates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessa
(ages 65+) of RCC patients. Only first VTE counted in rate estimates.
dRate ratios are unadjusted.and SEER reviewed this project for potential confidenti-
ality concerns prior to releasing the study data.
Results
The study population for the first series of analyses
consisted of 11,950 RCC patients 65 years of age and
older (median age = 75 years). Eighty-six percent of the
population was white, 8% of the population was black,
and 6% was another race. Fifty-nine percent of RCC pa-
tients were male. The distribution of cases by stage was
as follows: 52% localized, 19% regional, 21% distant, and
8% unstaged. The non-cancer comparison cohort was
similar in its distribution of age and race; however, the
proportion of males in the non-cancer population (37%)
was lower than in the RCC cohort (59%).
RCC patients
Incidence rate of VTEs among older RCC patients was
2.1-3.8 times higher during the 12-month period after
RCC diagnosis than the 12-month period prior to cancer
diagnosis (Table 1). Of all VTEs that occurred after diag-
nosis, DVTs occurred at the highest rate (108/ 1,000
person-years). The number of VTEs experienced in
discrete time periods after diagnosis and one-year inci-
dence proportions for the 12 month period among RCC
patients are displayed in Figure 1. Among RCC patients,
8.3% experienced a DVT, 2.4% experienced a PE, and
3.9% experienced OTEs in the 12 months after diagnosis
(Figure 1). Regardless of type of VTE, nearly 70% of
VTEs occurred in the first 90 days after RCC diagnosis:patients, before and after RCC diagnosis SEER-Medicare
CC diagnosis Incidence 12 months after RCC diagnosis
380/11,785 990/9,150
2.2 (29.1-35.7) 108.2 (101.6-115.2)
– 3.4 (3.0-3.8)
95/11,912 286/9,536
8.0 (6.5-9.8) 30.0 (26.6-33.7)
– 3.8 (3.0-4.7)
280/11,813 462/9,434
3.7 (21.1-26.7) 49.0 (44.6-53.7)
– 2.1 (1.8-2.4)
rombosis; PE = Pulmonary Embolism; OTE = Other thromboembolic event. OTE
butary (branch) occlusion, Nonpyogenic thrombosis of intracranial venous
s/thrombophlebitis of superficial veins of upper extremities, phlebitis/
ari syndrome, and venous embolism/thrombosis of renal vein.


























Figure 1 VTEs in discrete time intervals and incidence proportionsa in the 12 months after RCC diagnosisb. aIncidence proportions =
IP = 1-year overall incidence proportion defined as number of events divided by the beginning population at risk. bResults from SEER-Medicare
Data (1991–2003).
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67.7% (319/471).
Unadjusted analyses revealed that RCC patients with a
recent history of a VTE had substantially higher rates of
that specific VTE after RCC diagnosis than those with-
out history of that VTE (Table 2). Patients of advanced
or regional RCC stage had higher rates of VTEs after
diagnosis compared to patients with localized disease
(Table 2). Patients who received immunotherapy were
also more likely to experience all three VTEs, particu-
larly DVT. Patients who were treated with nephrectomy
were less likely to experience a DVT or PE after RCC
diagnosis (Table 2).
The strongest predictor of increased risk of a VTE in
the 12 months after RCC diagnosis was a recent history
of that particular VTE event (Table 3; HR range =
5.4-20.1). Stage at diagnosis, atherosclerosis, and kidney
disease were also significantly associated with an in-
creased risk of VTE. Predictors associated with de-
creased risk of VTE were prior use of central venous
catheter and recent experience of high-risk surgery.
Multivariate modeling was conducted to more closely
evaluate the association between CVD history, VTE his-
tory, and incidence of VTEs after RCC diagnosis. RCC
patients with a recent history of a CVD event (MI, IS,
congestive heart failure, angina, TIA) were no more
likely to have a VTE after RCC diagnosis than those
without CVD event history (results not shown). On the
other hand, a history of the specific VTE substantially
increased the risk of that venous event in the 12 months
after diagnosis (HR = 5.2-18.8) (Table 4). The association
between recent history of DVT and DVT occurrence
after diagnosis was modified by the presence of kidney
disease; among patients who did not have kidney disease,
the association was almost twice as strong (HR = 6.8,
95% CI = 5.4-8.7) as among those with kidney disease
(HR = 3.8, 95% CI = 2.9-5.1). The association betweenrecent history of PE and PE occurrence after diagnosis
was the strongest (HR = 18.9, 95% CI = 13.0-27.5) and
was not modified by any covariates. The association be-
tween having a recent history of OTE and OTE occur-
rence after diagnosis was modified by the presence of
kidney disease and sex. Among patients who did not
have kidney disease, the association between history of
OTE and OTE after diagnosis was nearly three times as
strong as among those with kidney disease (did not have
kidney disease: HR = 10.2, 95% CI 7.5-14.0; had kidney
disease: HR = 3.9, 95% CI = 2.5-6.4). The same associ-
ation was also much stronger among men (HR = 11.5,
95% CI = 8.4-15.7) than women (HR = 3.4, 95% CI =
2.1-5.6).
RCC patients compared to an age-matched, non-cancer
population
Older RCC patients were 1.5-1.8 times more likely to
have experienced a VTE in the recent past (i.e. 12 month
prior to RCC diagnosis) than non-cancer individuals
(Table 5). This was especially evident among those with-
out a recent history of a CVD event. The association be-
tween RCC and having a VTE during 12 months after
diagnosis was even stronger: RCC patients are 2.4-4.3
times more likely to experience a VTE event than age-
matched non-cancer individuals during the same time
frame (Table 5). Several factors modified these associa-
tions. The general pattern was that among patients with-
out strong CVD risk factors (e.g. history of CVD events
and diabetes), the association between RCC and VTEs
was stronger than among those with a CVD risk factor.
Discussion
To compare our results to those in the literature, we com-
bined our DVT and PE incidence and incidence density
estimates to determine an overall VTE incidence, com-
monly reported by others. Our combined (DVT + PE),
Table 2 Incidence rates of VTE among older RCC patients in the 12 months after cancer diagnosis
DVTa PEa OTEa
n = 11,950 RCC patients N / P-Yb Rate/1,000c (95% CI) N / P-Yb Rate/1,000c (95% CI) N / P-Yb Rate/1,000c (95% CI)
Age
65-69 144/1,593 90.4 (76.2-106.4) 39/1,657 23.5 (16.7-32.2) 59/1,638 36.0 (27.4-46.5)
70-74 306/2,883 106.2 (94.6-118.7) 84/3,011 27.9 (22.3-34.5) 170/2,965 57.4 (49.1-66.6)
75-79 270/2,436 110.8 (98.0-124.4) 84/2,527 33.3 (26.5-41.2) 121/2,512 48.2 (40.0-57.6)
80-84 175/1,479 118.3 (101.4-137.2) 60/1,546 38.8 (29.6-50.0) 75/1,539 48.7 (38.3-61.1)
85+ 95/759 125.2 (101.3-153.1) 19/795 23.9 (14.4-37.3) 37/781 47.4 (33.4-65.3)
Race
Black 104/709 146.6 (119.8-177.1) 28/753 37.2 (24.7-53.8) 35/751 46.6 (32.4-64.8)
White 838/7,908 106.0 (98.9-113.4) 248/8,227 30.1 (26.5-34.1) 405/8135 49.8 (45.1-54.9)
Other 46/520 88.5 (64.8-188.1) 10/542 18.5 (8.9-34.0) 21/534 39.3 (24.3-60.1)
Sex
Female 440/3,681 119.5 (108.6-131.2) 129/3,850 33.5 (28.0-39.8) 202/3,809 53.0 (46.0-60.9)
Male 550/5,469 100.6 (92.3-109.3) 157/5,686 27.6 (23.5-32.3) 260/5,625 46.2 (40.8-52.2)
History of VTEd
Yes 93/86 1086.7 (877.1-1,331.3) 24/25 974.3 (624.3-1,449.7) 37/77 482.8 (339.9-665.4)
No 897/9,065 99.0 (92.6-105.7) 262/9,511 27.6 (24.3-31.1) 425/9,357 45.4 (41.2-50.0)
History of CVDe
Yes 181/1,400 129.3 (111.1-149.5) 54/1,465 36.9 (27.7-48.1) 84/1,451 57.9 (46.2-71.7)
No 809/7,750 104.4 (97.3-111.8) 232/8,071 28.7 (25.2-32.7) 378/7,983 47.4 (42.7-52.4)
Disease stage
Localized 374/5,628 66.5 (59.9-73.5) 133/5,757 23.1 (19.3-27.4) 190/5,734 33.1 (28.6-38.2)
Regional 290/1,749 165.8 (147.3-186.1) 62/1,899 32.7 (25.0-41.9) 154/1,837 83.9 (71.1-98.2)
Distant 266/1,161 229.2 (202.5-258.5) 69/1,245 55.4 (43.1-70.2) 90/1,230 73.2 (58.8-89.9)
Immunotherapyf
Yes 78/376 207.3 (163.8-258.6) 17/407 41.7 (24.3-66.8) 27/398 67.9 (44.7-98.7)
No 912/8,774 103.9 (97.3-110.9) 269/9,128 29.5 (26.0-33.2) 435/9,036 48.1 (43.7-52.9)
Nephrectomy
Yes 665/6,963 95.5 (88.4-103.1) 204/7,250 28.1 (24.4-32.3) 341/7,164 47.6 (42.7-52.9)
No 325/2,188 148.6 (132.9-165.6) 82/2,286 35.9 (28.5-44.5) 121/2270 53.3 (44.2-63.7)
aVTE = venous thromboembolic events; RCC = renal cell cancer; DVT = Deep Vein Thrombosis; PE = Pulmonary Embolism; OTE = Other thromboembolic event. OTE
category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, Nonpyogenic thrombosis of intracranial venous
sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/
thrombophlebitis of other sites, gout with other specified manifestations, Budd-Chiari syndrome, and venous embolism/thrombosis of renal vein.
bN = number of VTE events; P-Y = person-years.
cRates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessary as these rates are intentionally representative of the older subpopulation
(ages 65+) of RCC patients. Only first VTE counted in rate estimates.
dHistory of VTE of interest in the 12 months before RCC diagnosis.
eHistory of CVD is defined as a history of any of the following events in the 12 months before RCC diagnosis: myocardial infarction, ischemic stroke, onset
congestive heart failure, angina, or TIA.
fImmunotherapy in our data (1991–2003) predominantly included Interferon alpha and IL-2 therapies.
Connelly-Frost et al. BMC Cancer 2013, 13:209 Page 5 of 10
http://www.biomedcentral.com/1471-2407/13/209one-year, post RCC incidence was 10.7% and incidence
density rate was 127/1,000 p-y. These estimates are higher
than what has been reported in the literature thus far
[2,6-8,10-12].
Our incidence results, however, are difficult to compare
to current literature because of method and study popula-
tion differences. Our analysis followed each patient for a
defined period after diagnosis or death to evaluateincidence over the full 12-month period after diagnosis;
however, many of the studies calculated an incidence pro-
portion (percent) based on whether the patient had a diag-
nosis of VTE during their initial hospitalization [7,10] or
during a randomly selected hospitalization [8]. Their esti-
mates of VTE among kidney cancer patients ranged from
0.8-7.6% per hospitalization. These are not comparable to
our estimate(s) because only one hospitalization has been
Table 3 Important Predictors of VTEs in the 12 months after RCC diagnosis, SEER-Medicare Data (1991–2003)a
n = 11,950 RCC patients DVTb (n = 990) P-Value PEb (n = 286) P-Value OTEb (n = 470) P-Value
HR (95% CI) HR (95% CI) HR (95% CI)
Male sex 0.8 (0.7-0.9) <0.001 0.8 (0.6- 1.0) 0.041 – –
Atherosclerosis 2.0 (1.7-2.3) <0.001 2.5 (2.0-3.2) <0.001 1.7 (1.4-2.1) <0.001
Diabetes 1.2 (1.1-1.4) 0.004 – – – –
Hypercholesterolemia – – – – 1.3 (1.1-1.6) 0.012
Kidney disease 1.9 (1.6-2.1) <0.001 1.6 (1.2- 2.0) <0.001 1.4 (1.2-1.7) 0.001
Varicose veins 2.2 (1.6-3.1) <0.001 – – – –
History of cancer diagnosis – – 1.5 (1.0- 2.2) 0.033 – –
History of VTEc 5.4 (4.4-6.4) <0.001 20.1 (13.8-29.2) <0.001 7.6 (5.9-9.9) <0.001
Chemotherapy 1.8 (1.4-2.2) <0.001 – – 1.4 (1.0-2.0) 0.048
Central venous catheterd 0.4 (0.3-0.4) <0.001 0.3 (0.2-0.5) <0.001 0.5 (0.4-0.7) <0.001
High-risk surgerye 0.4 (0.3-0.6) <0.001 0.5 (0.3-0.8) 0.003 0.5 (0.4-0.7) <0.001
Stage
Regional versus localized 2.5 (2.2-2.9) <0.001 1.6 (1.2-2.1) 0.002 2.6 (2.1-3.2) <0.001
Distant versus localized 2.6 (2.2-3.0) <0.001 1.9 (1.4-2.5) <0.001 1.7 (1.3-2.2) <0.001
aAll models adjusted for age and race (age and race were not statistically significant predictors of any VTEs).
bDVT = Deep Vein Thrombosis; PE = Pulmonary Embolism; OTE = Other thromboembolic event. OTE category includes the following diagnoses: central retinal vein
occlusion, venous tributary (branch) occlusion, Nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower
extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations,
Budd-Chiari syndrome, and venous embolism/thrombosis of renal vein.
cHistory of VTE in the 12 months before RCC diagnosis.
dCentral venous catheter (CVC) in the 12 months after diagnosis. CVCs that occurred less than 30 days before a TE event were excluded.
eHigh-risk surgery = cardiac or vascular surgeries in the year after RCC diagnosis. Procedures that happened less than 30 days before a TE event were excluded
because of the nature of Medicare claims (Date ranges are used for procedures as we wanted to make sure that the procedure was not part of the treatment for
the VTE outcome of interest).
Table 4 Relative risk of VTE after RCC diagnosis, by recent VTE historya
n = 11,950 DVTb PEb OTEb
HR (95% CI) HR (95% CI) HR (95% CI)
Overall hazard ratios 5.2 ( 4.4-6.3) 18.8 (13.0-27.5) 7.1 (5.5-9.2)
P-Valuec <0.001 <0.001 <0.001
Effect measure modifiers
Kidney disease
Yes 3.8 (2.9-5.1) ns 3.9 (2.5- 6.4)
No 6.8 (5.4-8.7) ns 10.2 (7.5-14.0)
P-Value 0.003 0.432 <0.001
Sex
F ns ns 3.4 (2.1- 5.6)
M ns ns 11.5 (8.4-15.7)
P-Value 0.818 0.239 <0.001
aAll models adjusted for atherosclerosis, kidney disease, and sex. Hazard ratios compared the risk of a VTE in the 12 months after diagnosis for those with versus
without a recent history of the specific VTE of interest. Results from SEER-Medicare Data (1991–2003).
bDVT = Deep Vein Thrombosis; PE = Pulmonary Embolism; OTE = Other thromboembolic event. OTE category includes the following diagnoses: central retinal vein
occlusion, venous tributary (branch) occlusion, Nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower
extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations,
Budd-Chiari syndrome, and venous embolism/thrombosis of renal vein.
cP-Value for the difference between stratum specific estimates.
ns = no statistically significant difference between strata.
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Table 5 Relative risk of VTE before and after diagnosis (or index date): RCC versus non-cancer cohorta
DVTb PEb OTEb
Before After Before After Before After
OR (95% CI) HR (95% CI) OR (95% CI) HR (95% CI) OR (95% CI) HR (95% CI)
Overall 1.6 (1.3-1.9) 3.6 (3.1-4.1) 1.8 (1.3-2.6) 4.3 (3.2-5.7) 1.5 (1.2-1.8) 2.4 (2.0-2.8)
P-valuec <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Effect measure modifiers
Atherosclerosis Yes ns 2.0 (1.5-2.6) ns ns ns ns
No ns 4.1 (3.5-4.9) ns ns ns ns
P-valuec 0.384 <0.001 0.112 0.275 0.364 0.100
Central venous catheterd Yes ns ns ns 0.7 (0.1-6.0) ns ns
No ns ns ns 4.9 (3.7-6.5) ns ns
P-value c 0.134 0.081 0.977 0.161 0.440 0.882
Diabetes Yes 1.1 (0.8-1.5) 2.4 (1.9-3.1) ns ns ns ns
No 1.8 (1.4-2.2) 4.2 (3.6-5.1) ns ns ns ns
P-value c 0.003 <0.001 0.280 0.332 0.181 0.108
High-risk surgerye Yes ns 1.4 (0.7-2.8) ns 1.2 (0.4-3.7) ns ns
No ns 3.8 (3.3-4.4) ns 4.7 (3.5-6.3) ns ns
P-value c 0.129 <0.001 0.698 0.030 0.714 0.387
History of CVDf Yes 1.1 (0.8-1.5) 2.0 (1.6-2.6) ns 2.5 (1.5-4.0) 1.0 (0.7-1.4) 1.6 (1.2-2.2)
No 1.8 (1.4-2.2) 4.7 (3.9-5.6) ns 5.2 (3.6-7.4) 1.7 (1.3-2.1) 2.7 (2.2-3.3)
P-value c 0.002 <0.001 0.366 0.005 0.001 <0.001
Kidney disease Yes ns 1.8 (1.3-2.5) ns 1.3 (0.7-2.3) ns 1.3 (0.8-2.2)
No ns 4.0 (3.4-4.6) ns 5.2 (3.8-7.2) ns 2.5 (2.1-3.0)
P-value c 0.292 <0.001 0.940 <0.001 0.343 0.014
aAll models adjusted for age at index date (matching factor), sex, kidney disease and stratified by important effect measure modifiers. Odds ratios compared risk
of a VTE in the 12 months before diagnosis (or index date) and hazard ratios compared risk of VTE in the 12 months after diagnosis (or index date). Results from
SEER-Medicare Data (1991–2003). RCC Patients (n = 11,950); Non-Cancer Control Group (n = 11,918).
bDVT = deep vein thrombosis, PE = pulmonary embolism, OTE = other thrombolic event. OTE includes: central retinal vein occlusion, venous tributary (branch)
occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis
of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd-Chiari syndrome, venous
embolism/thrombosis of renal vein and portal vein thrombosis.
cP-Value for the difference between stratum specific estimates.
dCentral venous catheter (CVC) in the 12 months after diagnosis. CVCs that occurred less than 30 days before a TE event were excluded.
eHigh-risk surgery = cardiac or vascular surgeries in the year after index date or RCC diagnosis. Procedures that happened less than 30 days before a TE event
were excluded because of the nature of Medicare claims (Date ranges, rather than exact dates, are used for procedures and we wanted to make sure that the
procedure was not part of the treatment for the TE outcome of interest.).
fHistory of CVD = any of the following CVD events in the year before the analysis period: MI, IS, onset congestive heart failure, angina, or TIA (analysis period =
12 months before diagnosis or index date or 12 months after diagnosis or index date).
ns = no statistically significant difference between strata.
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to ours in that they looked at all hospitalizations for each
patient over a period of time; however, they also presented
their results per hospitalization instead of per person or
person-years (VTE incidence of 20/1,000 hospitalizations)
[12]. It is unclear what the average length of follow-up
was in their study and their study population was also
substantially younger than ours, with ages ranging from
40–79 compared to our study age range of 65–101, with a
median age of 75.
A few other studies presented cumulative incidence
and incidence density results for kidney cancer patients;
however, their study populations were vastly differentfrom ours. Blom et al. found that 1.3% of kidney cancer
patients (and 12.6/1,000 p-y) had a VTE in the 6 months
after cancer diagnosis; however, researchers only in-
cluded patients who visited an anticoagulant clinic, not
patients who were hospitalized for treatment [6]. Their
estimate is significantly lower than ours (127/1,000 p-y)
and likely an underestimate of the rate in the general
kidney cancer population because sicker individuals,
who were unable to visit this ambulatory clinic, were not
given the opportunity to present as a VTE case in their
study population. They also had a younger population
(median age = 64) than ours. Chew et al. performed their
analysis very similarly to ours; however, they excluded all
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of post kidney cancer VTE incidence (2-yr cumulative in-
cidence: local: 1.3%, regional: 3.8, remote 3.5% and 2-yr in-
cidence densities of 13, 37, and 60 per 1,000 p-y) are likely
lower than ours because they have excluded the highest
risk group of patients from their analysis. Sallah et al.
found that 22.6% of kidney cancer patients developed
VTE over an average of 26 months [11]. Their estimate of
cumulative incidence was higher than ours; however, their
sample size was very small (n = 31), their study population
was much younger (median age = 60 yrs), and their aver-
age period of follow-up was twice as long as ours.
Our results indicate that the risk of VTE is highest in
the first 90 days after RCC diagnosis. Blom et al. also
found the risk of VTE particularly high during the first
few months after cancer diagnosis; however, they could
draw no conclusion about kidney cancer, in particular,
due to limited sample size for that cancer (n = 8) [15].
The risk of VTE was significantly higher among distant
metastasized kidney cancers in the Blom study, as well
[15]. This is similar to our finding that regional and dis-
tant RCC patients were at increased risk of VTE com-
pared to local RCC cases.
The major risk factors for venous thromboembolisms
among cancer patients reported in the literature are
increased age, female sex, African American race, renal
disease, infection, pulmonary disease, obesity, arterial
thromboembolism, inherited prothrombotic mutations,
prior history of VTE, performance status, advanced stage
cancer, major surgery, hospitalization, chemotherapy,
hormone therapy, anti-angiogenic agents, erythropoiesis-
stimulating agents, transfusions, and central venous
catheters [4,8,13,16,17]. In our predictive model, many
of these risk factors proved to be predictors of VTEs in
the 12 months after RCC diagnosis. Unadjusted results
presented in Table 2 suggested that immunotherapy
might be an important predictor of VTEs in our data;
however, after adjustment for stage and other important
risk factors (Table 3), immunotherapy was not a statisti-
cally significant predictor of VTEs.
A few interesting differences are worth discussion.
Atherosclerosis was a strong predictor for DVT, PE and
OTE events. This condition is not generally mentioned
as a risk factor for VTE among cancer patients; however,
cardiovascular literature has suggested a link between
these two conditions [18-21]. Another interesting result
was that central venous catheter (CVC) and high-risk
surgery decreased the risk VTE in our data. Decreased
risk in this subgroup of patients is likely due to the close
monitoring and prophylactic treatment for venous
thromboses in surgical and catheterization situations.
An important component of our analysis was the
evaluation of VTE history as a risk factor for future VTE
events. Our results suggest that VTE history is the mostimportant factor to consider in evaluating risk of future
VTE in RCC patients. There are no other studies in the
current literature that quantify the association between
VTE history and RCC; however, this result is consistent
with broader studies of VTE among cancer patients [4,17].
Finally, our analysis compared the risk of VTE events
in RCC versus non-cancer patients both before and after
RCC diagnosis. Our study found that RCC patients were
1.5-1.9 times more likely to have experienced a VTE in
the recent past (i.e. 12 month before RCC diagnosis)
than non-cancer individuals. White et al. reported a simi-
lar result: the standardized incidence ratio of observed
versus expected RCC patients was 2.5 among those with a
history of VTE [22]. No other published studies had suffi-
cient numbers to address the relation between VTE and
subsequent RCC diagnosis. These results support the
common theory that VTE could be a risk marker for an
ensuing cancer diagnosis [4,23,24].
Our study found that RCC patients were also 3.6 times
more likely to experience a DVT and 4.3 times more
likely to experience a PE event in the 12 months after
RCC diagnosis than age-matched non-cancer individuals
during the same time frame. Stein et al. reported a slightly
weaker association: RCC cancer patients were 2.0 times
more likely to have a DVT and 1.7 times more likely to
have a PE than non-cancer patients [12]. The study popu-
lation was significantly younger in the Stein study and they
did not adjust for confounders or evaluate effect modifiers.
Blom et al. also compared VTE incidence among kidney
cancer patients versus non-cancer patients (OR = 6.2, 95%
CI 0.8-46.5); however, there were only 8 kidney cancer
cases in their case–control study [15].
There are several strengths of note for this study. To
our knowledge, this is the first study to examine VTEs
among older RCC patients. In this analysis we were able
to focus on RCC patients in particular, rather than kid-
ney cancer patients overall, because of the availability of
detailed histological information in SEER. The RCC
patient cohort was large (n = 11,950) allowing us to pro-
duce precise effect measure estimates, even after stratifi-
cation. Unlike many published studies, which combined
TE events into one outcome group, we examined three
individual venous outcome groups (DVT, PE and OTEs)
based on ICD-9 diagnostic codes. The wealth of the data
in the SEER-Medicare database allowed us to quantify
the occurrence of TE events before RCC diagnosis and
during various time periods after RCC diagnosis, and to
make comparisons between RCC patients and age-
matched non-cancer individuals. Furthermore, we were
able to adjust for and/or stratify by important covariates
in our analysis. All estimates for incidence of VTEs
among RCCs in previous literature were generated from
studies that looked at multiple cancers and presented
unadjusted incidence estimates for specific cancers,
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variate analyses on RCC patients nor did they investigate
the timing of VTE events among RCC patients.
As in any study, limitations were present. The results
based on this older cohort (i.e., 65 years or older) are
generalizable only to those of the same age group. Also,
information on some behavioral risk factors such as
smoking, sedentary lifestyle, immobility, and CVD family
history was unavailable. Oral prescription information
was also unavailable, precluding the evaluation of anti-
platelet therapy or anti-coagulant use. Finally, we had no
access to information about potential predictive bio-
markers such as elevated platelet or leukocyte counts,
tissue factor, soluble p-Selectin, D-dimer, factor V Leiden,
and prothrombin 20210A mutations [13,15,25].Conclusion
This is the first study to perform an in depth analysis of
VTEs among RCC patients. Our results indicate that
RCC patients are at increased risk of VTEs after cancer
diagnosis and that patients diagnosed with RCC are
more likely to have had a VTE within 12 months before
their RCC diagnosis. VTEs are common and serious co-
morbidities that should be closely monitored in older
RCC patients, particularly during the first three months
after diagnosis and among those with a recent history of
a VTE.
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